Xoft, Inc.
11
0
1
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
27.3%
3 terminated/withdrawn out of 11 trials
70.0%
-16.5% vs industry average
9%
1 trials in Phase 3/4
71%
5 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Comparison of eBX and Mohs Surgery for Treatment of Early-stage Non-melanoma Skin Cancer a Matched Pair Cohort Study.
Role: lead
Safety and Efficacy Study of the Xoft® Axxent® eBx® IORT System®
Role: lead
Post-market Multi-Center RETRO-Prospective Study to Assess Long-term Clinical Outcomes NMSC Patients Treated With eBx
Role: lead
Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab
Role: lead
Electronic Brachytherapy for the Treatment of NMSC
Role: lead
An Efficacy Study of the Xoft® Axxent® eBx® IORT System® "Lite"
Role: lead
Feasibility Study of the Xoft® Axxent® Electronic Brachytherapy System for the Treatment of Cervical Cancer
Role: lead
Post Market Study Using the Xoft Axxent System
Role: lead
Intra-Operative Radiation Therapy Immediately Following Resection of Early Stage Breast Cancer
Role: lead
Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer
Role: lead
Feasibility Study Using the Xoft System for the Treatment of Endometrial Cancer
Role: lead
All 11 trials loaded